Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Decision to use commercially supplied Idefirix® (imlifidase) in approved indication by the European Medicines Agency (EMA)1,2 · Decision provides highly sensitized patients in France with the opportunity to immediately receive Idefirix® as desensitization treatment · Commercial launch activities for Idefirix® in Europe continue to progress Lund, Sweden, February 25, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix® (imlifidase)